ERA4Health Partnership: Call for proposals 2025: Fostering Pragmatic Comparative-Effectiveness Trials in Non-communicable Diseases (EffecTrial)
Publication planned: 20 November, 2024
Deadline for preproposal submission: 28 January, 2025
Webinar Infoday: 27 November, 2024
Deadline for full proposal submission: 17 June, 2025
The Partnership “Fostering a European Research Area for Health” (ERA4Health) aims at establishing a flexible and effective coordination between funding organisations in the European Research Area (ERA) in priority areas addressing European Public Health Needs. This Partnership brings the opportunity to increase European transnational collaborative research funding by creating a funding body for joint programming. Under this umbrella, ERA4Health pre-announces a first Joint Transnational Call (JTC) in multi-country Investigator-Initiated Clinical Studies (IICS) on “Fostering Pragmatic Comparative-Effectiveness Trials in Non-communicable Diseases” (EffecTrial)
The aims of the call are:
- to support randomised, interventional and pragmatic comparative-effectiveness multi-country Investigator-Initiated Clinical Studies (IICS).
- to encourage and enable transnational collaboration between clinical/public health research teams (from hospital/ public health, healthcare settings and other healthcare organisations) that conduct comparative-effectiveness multi-country IICS.
Proposals should address all the 4 following points:
1) Be a pragmatic comparative effectiveness trials, designed as randomised interventional trials.
2) Compare the use of currently approved healthcare interventions either to each other or to the current standard of care.
3) They shall consider healthcare interventions which could include but would not be limited to: diagnostic, screening, prevention and treatment interventions (pharmacological and non-pharmacological procedures like nutrition and/or lifestyle interventions, surgery, prognosis methods, use of medical devices, eHealth and digital interventions and other health interventions).
4) These interventions shall have high public relevance only in the fields of these specific diseases or conditions (that are of equal importance):
o Cardiovascular diseases
o Metabolic disorders
o Nutrition and lifestyle-related diseases
o Non-communicable respiratory diseases
The focus of the multi-country Investigator-Initiated Clinical Studies should primarily address at least one of the abovementioned principal diseases/conditions, although the proposals can also address several of the mentioned diseases/conditions and/or other related comorbidities.
Further information on the Call Pre-announcement: https://era4health.eu/calls/pre_effectrial.php
Link to the webinar of Pre-announcement:
https://era4health.eu/news/blogdetail.php?id=5